Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 12 | 2022 | 23 | 3.790 |
Why?
|
| Racism | 4 | 2023 | 35 | 1.620 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 2504 | 1.150 |
Why?
|
| Minority Groups | 6 | 2018 | 251 | 1.120 |
Why?
|
| Mammography | 3 | 2024 | 114 | 1.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 332 | 0.900 |
Why?
|
| Health Equity | 1 | 2023 | 57 | 0.790 |
Why?
|
| Medicine | 2 | 2022 | 97 | 0.790 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 274 | 0.770 |
Why?
|
| Physicians | 5 | 2020 | 579 | 0.740 |
Why?
|
| Sex Distribution | 4 | 2019 | 297 | 0.710 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1126 | 0.700 |
Why?
|
| Education, Medical, Graduate | 4 | 2020 | 515 | 0.680 |
Why?
|
| Mass Screening | 4 | 2024 | 783 | 0.680 |
Why?
|
| Personnel Selection | 2 | 2018 | 61 | 0.680 |
Why?
|
| Sexism | 3 | 2022 | 38 | 0.650 |
Why?
|
| Cultural Diversity | 5 | 2018 | 63 | 0.630 |
Why?
|
| Sexual Health | 1 | 2018 | 9 | 0.620 |
Why?
|
| Health Communication | 1 | 2018 | 26 | 0.620 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 256 | 0.610 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 46 | 0.600 |
Why?
|
| Faculty, Medical | 6 | 2020 | 262 | 0.590 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1598 | 0.580 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 174 | 0.560 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2024 | 163 | 0.530 |
Why?
|
| Survivors | 1 | 2018 | 339 | 0.520 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 62 | 0.500 |
Why?
|
| Mastectomy | 1 | 2015 | 64 | 0.500 |
Why?
|
| Brachytherapy | 1 | 2016 | 75 | 0.480 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 97 | 0.470 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 1531 | 0.470 |
Why?
|
| Vagina | 1 | 2016 | 195 | 0.450 |
Why?
|
| Radiotherapy Dosage | 3 | 2024 | 186 | 0.450 |
Why?
|
| Health Personnel | 1 | 2018 | 505 | 0.440 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 326 | 0.430 |
Why?
|
| Sex Ratio | 1 | 2012 | 12 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 4 | 2020 | 497 | 0.410 |
Why?
|
| United States | 18 | 2024 | 10766 | 0.400 |
Why?
|
| Neoplasms | 2 | 2023 | 2763 | 0.390 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1460 | 0.380 |
Why?
|
| Female | 26 | 2024 | 66236 | 0.360 |
Why?
|
| Chemoradiotherapy | 4 | 2024 | 104 | 0.360 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 656 | 0.350 |
Why?
|
| Humans | 37 | 2024 | 124307 | 0.340 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 1890 | 0.340 |
Why?
|
| Radiation Oncologists | 2 | 2020 | 3 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3575 | 0.310 |
Why?
|
| Administrative Personnel | 2 | 2019 | 24 | 0.300 |
Why?
|
| Aged | 11 | 2024 | 19481 | 0.300 |
Why?
|
| Internship and Residency | 4 | 2022 | 1177 | 0.290 |
Why?
|
| Middle Aged | 11 | 2024 | 26451 | 0.270 |
Why?
|
| Veterans | 3 | 2022 | 1752 | 0.260 |
Why?
|
| Male | 20 | 2024 | 60964 | 0.260 |
Why?
|
| Physicians, Women | 2 | 2017 | 47 | 0.260 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2024 | 141 | 0.250 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 298 | 0.240 |
Why?
|
| Students, Medical | 2 | 2023 | 356 | 0.230 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 106 | 0.220 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.220 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 359 | 0.220 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 37 | 0.210 |
Why?
|
| Sexual Harassment | 1 | 2022 | 18 | 0.200 |
Why?
|
| Prognosis | 3 | 2020 | 4549 | 0.190 |
Why?
|
| Abortion, Induced | 1 | 2022 | 74 | 0.190 |
Why?
|
| Breast | 1 | 2022 | 215 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 79 | 0.180 |
Why?
|
| Pharyngeal Muscles | 1 | 2020 | 11 | 0.180 |
Why?
|
| Blood Volume | 1 | 2020 | 80 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12292 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 605 | 0.160 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 130 | 0.160 |
Why?
|
| Schools, Medical | 1 | 2019 | 111 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2019 | 102 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2021 | 643 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2019 | 246 | 0.150 |
Why?
|
| Prostatectomy | 1 | 2019 | 334 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 606 | 0.150 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 79 | 0.150 |
Why?
|
| Sex Factors | 2 | 2019 | 1268 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2023 | 518 | 0.150 |
Why?
|
| Heart | 1 | 2022 | 717 | 0.140 |
Why?
|
| Employee Performance Appraisal | 1 | 2017 | 12 | 0.140 |
Why?
|
| Achievement | 1 | 2017 | 31 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2018 | 175 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2019 | 358 | 0.140 |
Why?
|
| Patient Preference | 1 | 2018 | 119 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 305 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2019 | 376 | 0.140 |
Why?
|
| Women, Working | 1 | 2016 | 9 | 0.140 |
Why?
|
| Hematology | 1 | 2017 | 37 | 0.130 |
Why?
|
| Medical Oncology | 2 | 2017 | 207 | 0.130 |
Why?
|
| Radiology, Interventional | 1 | 2016 | 28 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 1246 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 3 | 2022 | 216 | 0.130 |
Why?
|
| Specialization | 1 | 2016 | 75 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 142 | 0.120 |
Why?
|
| Time Factors | 4 | 2020 | 6272 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 426 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 355 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2022 | 4731 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 859 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 664 | 0.100 |
Why?
|
| Physics | 2 | 2022 | 7 | 0.100 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2011 | 17 | 0.100 |
Why?
|
| Patient Selection | 1 | 2015 | 689 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1218 | 0.090 |
Why?
|
| Nose Neoplasms | 1 | 2011 | 32 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 69 | 0.090 |
Why?
|
| Registries | 2 | 2016 | 1410 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5105 | 0.080 |
Why?
|
| Disease Progression | 1 | 2015 | 2039 | 0.080 |
Why?
|
| Consensus | 2 | 2022 | 628 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6469 | 0.080 |
Why?
|
| Mentors | 2 | 2022 | 143 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2023 | 548 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2024 | 6071 | 0.070 |
Why?
|
| Adult | 5 | 2024 | 29385 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 670 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 3722 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2015 | 3382 | 0.060 |
Why?
|
| Career Choice | 2 | 2018 | 143 | 0.060 |
Why?
|
| Age Factors | 2 | 2024 | 2802 | 0.060 |
Why?
|
| Carboplatin | 1 | 2024 | 76 | 0.060 |
Why?
|
| Medical Overuse | 1 | 2024 | 25 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2024 | 144 | 0.060 |
Why?
|
| Social Identification | 1 | 2023 | 14 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2024 | 124 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2024 | 160 | 0.050 |
Why?
|
| Unemployment | 1 | 2023 | 20 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2024 | 137 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 28 | 0.050 |
Why?
|
| Developed Countries | 1 | 2022 | 36 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 470 | 0.050 |
Why?
|
| Risk Factors | 1 | 2015 | 10141 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2024 | 316 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2024 | 287 | 0.050 |
Why?
|
| Cause of Death | 1 | 2023 | 468 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2022 | 125 | 0.040 |
Why?
|
| Deglutition | 1 | 2020 | 49 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 288 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 80 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 315 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2020 | 165 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 199 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2020 | 142 | 0.040 |
Why?
|
| Budgets | 1 | 2019 | 17 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2019 | 138 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 2020 | 255 | 0.040 |
Why?
|
| Efficiency | 1 | 2019 | 61 | 0.040 |
Why?
|
| Employment | 1 | 2019 | 67 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1017 | 0.040 |
Why?
|
| Spouses | 1 | 2019 | 66 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 669 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 170 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 581 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1236 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1254 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 471 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 3080 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 520 | 0.030 |
Why?
|
| Leadership | 1 | 2019 | 228 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 1491 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 872 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 377 | 0.030 |
Why?
|
| Forecasting | 1 | 2018 | 350 | 0.030 |
Why?
|
| Education | 1 | 2015 | 107 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2089 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2011 | 5 | 0.020 |
Why?
|
| Stomatitis | 1 | 2011 | 13 | 0.020 |
Why?
|
| Radiodermatitis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2011 | 51 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 2971 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2011 | 50 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 277 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 342 | 0.020 |
Why?
|
| Quality of Life | 1 | 2019 | 1943 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7169 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 16228 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 8974 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 19300 | 0.010 |
Why?
|
| Child | 1 | 2011 | 24435 | 0.010 |
Why?
|